Mammalian degenerin (MDEG) is a member of the amiloride-sensitive sodium ion channel family, and its site-directed active mutant (MDEG-G430F) induces massive Na ϩ influx into cells, leading to cell ballooning and cell bursting. We attempted a novel therapeutic approach for gastric cancers by transferring MDEG-G430F into cancer cells using tumor-specific promoters. In carcinoembryonic antigen (CEA)-producing gastric cancer cells, the level of cell death observed when MDEG-G430F was used with a CEA promoter was similar to that observed when using a potent nonspecific promoter such as the cytomegalovirus promoter. In an in vivo study, fusogenic liposome complexes containing MDEG-G430F driven by the CEA promoter were injected intraperitoneally into CEA-producing gastric cancer cells in a mouse peritoneal dissemination model. Although all 15 of the control mice were dead by 50 days postinoculation, 13 of the 15 mice treated with MDEG-G430F survived. These results indicate that transferring MDEG-G430F into cancer tissues using tumor-specific promoters can achieve striking and selective cancer cell death irrespective of the transcriptional efficiency of the promoters used in vivo, and suggest that this approach is a promising new strategy for cancer gene therapy.
C ancer gene therapy must target cancer cells to be effective. The promoter element of tumor-expressing molecules can be used to induce specific expression of the transfected genes in the tumor. For example, expression of carcinoembryonic antigen (CEA) is highly specific in tumor cells. Previous studies demonstrated that the 440-bp sequence upstream from the transcriptional start site of the CEA gene exhibits potent promoter activity in CEA-producing cells. 1, 2 Gastric cancers mostly produce CEA, 3 and the CEA promoter has been employed in gastric cancer cells to induce tumor-specific gene expression. 4 However, tumor-specific promoters induce less gene expression, than do virus promoters, such as the simian virus 40 and cytomegalovirus (CMV) promoters. 5 Therefore, we sought to identify a gene whose expression could induce tumor cell death regardless of the transcriptional efficiency of the promoters.
Mammalian degenerin (MDEG) is a member of the highly amiloride-sensitive sodium ion channel family. 6, 7 MDEG-G430F is a site-directed mutant of MDEG in which glycine430 has been replaced by phenylalanine430. MDEG-G430F induces massive Na ϩ influx into cells, irrespective of the level of expression. This characteristic of mutated MDEG allowed us to test a new approach to cancer therapy in which MDEG-G430F was transferred into cancer cells driven by a tumor-specific promoter to target cancer cells specifically and efficiently.
MATERIALS AND METHODS

Cell culture
MKN45-P cells, derived from human gastric cancer, were incubated as described previously. 8 HepG2 cells, derived from human hepatoma, were incubated in the medium recommended by the American Type Culture Collection (Manassas, Va). In the present study, MKN45-P was used as the CEAproducing cell line and HepG2 was used as the CEA-nonproducing cell line.
Preparation of mutated MDEG
MDEG cDNA was cloned from a Sprague-Dawley rat brain cDNA library according to a previous report 9 and subcloned into pBluescript-SK(Ϫ) (Stratagene, La Jolla, Calif), referred to as pBlueG430. The HindIII-ApaI-digested fragment containing the full-length coding region of MDEG cDNA was subcloned into the pCDNA3 vector (Invitrogen, Carlsbad, Calif), referred to as CMVpCDNA3 MDEG-G430. The mutant clone in which glycine430 was replaced by phenylalanine430 was prepared using the QuickChange Site-Directed Mutagenesis kit (Stratagene) with the 5Ј phosphorylated primers CCACCGATGTCAAAAAGTAAGGCAGC and TCA-GATGGGACTGTTCATTGGTGCTAGTCT. After confirmation by sequence analysis, the mutant was named CMVpCDNA3 MDEG-G430F.
Promoter assay
To assess the promoter activity, the pGL3-basic luciferase reporter vector (Promega, Madison, Wis) was used. The CMV promoter element from pCDNA3 or the CEA promoter from pCEA-CAT 2 were subcloned into the pGL3-basic plasmid vector between the BglII and HindIII sites, referred to as CMV-pGL3B and CEA-pGL3B, respectively.
MKN45-P or HepG2 cells (1 ϫ 10 5 cells/well) on 6-well plates (Becton Dickinson Labware, Lincoln Park, NJ) were transfected with CMV-pGL3B, CEA-pGL3B, or pGL3-basic plasmid. Each transfectant contained the luciferase expression plasmid (8.75 g) and Tfx-20 reagent (26.25 g, 4:1 charge ratio of Tfx-20 reagent to DNA; Promega). Medium was changed at 2 hours after the addition of the plasmid/cationic liposome complexes. After incubation for 1 day, the cell extracts were subjected to a luciferase assay (Promega), and luciferase activity was determined according to the manufacturer's protocol. Values are expressed as the means of four independent experiments.
Construction of expression vectors
In place of the CMV promoter element, the BglII-HindIIIdigested fragments of the CEA promoter from pCEA-CAT (a kind gift of Drs. Hayashi and Osaki, Department of Medicine III, Osaka University Graduate School of Medicine) were inserted into CMVpCDNA3 MDEG-G430F and labeled CEApCDNA3 MDEG-G430F. This plasmid, which is driven by the CEA promoter, produced the active mutant ion channel MDEG-G430F.
In vitro cell-killing effect MKN45-P or HepG2 cells were plated on 96-well plates (10 4 cells/well; Becton Dickinson Labware) and transfected using cationic liposomes mediated by three different MDEG-G430F expression plasmids (CMVpCDNA3 MDEG-G430F, CEApCDNA3 MDEG-G430F, or the mock-transfected plasmid) on day 1. The number of tumor cells was measured using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The morphologic changes of the transfected cells were examined on 6-well plates.
In vivo cell-killing effect on an animal model Specific pathogen-free, 4-week-old female BALB/c nude mice were obtained from Japan SLC (Hamamatsu, Japan) to receive intraperitoneal (i.p.) injections of the human gastric cancer cell line MKN45-P. MKN45-P has a high potential for developing peritoneal dissemination with massive ascites. 8 The in vivo experimental design is shown in Figure 1 . MKN45-P cells (1 ϫ 10 6 ) were injected into the peritoneal cavities of each female BALB/c nude mouse on day 0.
The inoculated mice were divided into three groups: group 1 (experimental group; n ϭ 15) was treated with fusogenic liposomes containing the CEApCDNA3 MDEG-G430F plasmid (optical density (OD) 540 ϭ 0.25); group 2 (mock group; n ϭ 15) was treated with an i.p. injection of 100 L of fusogenic liposome containing the CEApCDNA3 plasmid (OD 540 ϭ 0.25); group 3 (control group; n ϭ 15) was treated with fusogenic liposome only. Fusogenic liposomes containing plasmids were prepared as described previously. 10 The three groups displayed no significant differences in CEA levels on day 3 (one-way analysis of variance (ANOVA) and post-hoc test using the Bonferroni/Dunn method). The treatment described above was started on day 3 and repeated once a week for each group. Serum CEA levels were measured each week and the mortality rate was monitored.
Statistical analysis
All statistical analyses were performed using StatView 4.5 on a Macintosh computer. One-way ANOVAs with post hoc analyses using the Bonferroni/Dunn method were used to examine differences in CEA levels between groups. A P value of Ͻ0.05 was considered statistically significant.
RESULTS
When MKN45-P or HepG2 cells were transfected with CMVpCDNA3 MDEG-G430F using cationic liposomes, the transfected cells exhibited cell ballooning, resulting in cell bursting (data not shown). Promoter activity levels were measured in CEA-producing gastric cancer cells and in CEA-nonproducing hepatoma cells using the luciferase assay (Fig 2) . In CEA highly producing MKN45-P cells, the CEA-promoter was active, but the activity level was only 9.8% of that of the CMV promoter; in CEA-nonproducing HepG2 cells, the CMV promoter exhibited high activity, whereas CEA promoter activity was at baseline levels.
These observations led us to examine the effects of MDEG-G430F driven by the above tissue-specific promoters on cell death using the transient transfection method. In MKN45-P cells, the CEA-producing gastric cancer cells (MDEG-G430F) driven by the CEA promoter exhibited cell-killing effects similar to those exhibited by MDEG-G430F cells driven by the CMV promoter. Conversely, in HepG2 cells, MDEG-G430F driven by the CEA promoter had no cell-killing effect (Fig 3) . Light-microscopic study revealed that the MKN45-P cells transfected by MDEG-G430F and driven by the CEA promoter were damaged in their (Fig 4) . Finally, the anti-cancer effects of MDEG-G430F in a mouse peritoneal dissemination model were examined in vivo. Mice with i.p. dissemination had numerous tumors in a variety of sizes in the peritoneal cavity; therefore, it was impossible to estimate tumor growth parameters accurately, such as the number of tumors or the tumor size. Because MKN45-P cells produce CEA, tumor growth was estimated by measuring the serum CEA level instead of measuring tumor weight or size. The serum CEA levels gradually increased both in mice in the mock group and in those of the control group, although there was no significant difference between the two groups. The serum CEA levels in the mice of the mock group and in the mice of the control group increased to 36.1 Ϯ 14.7 ng/mL and 27.1 Ϯ 14.4 ng/mL at 3 days, 107.9 Ϯ 63.2 ng/mL and 97.6 Ϯ 62.9 ng/mL at 10 days, 579.4 Ϯ 142.4 ng/mL and 653.9 Ϯ 185.8 ng/mL at 17 days, 1056.1 Ϯ 209.7 ng/mL and 976.9 Ϯ 163.9 ng/mL at 24 days, and 1807.6 Ϯ 207.6 ng/mL and 1877.5 Ϯ 276.7 ng/mL at 31 days, respectively (Fig 5) . All of the mice in both groups displayed peritoneal dissemination with massive ascites and severe distended abdomens (Fig 6) , resulting in death within 40 days after the inoculation of MKN45-P cells. In contrast, there was a significant difference in the serum CEA levels of mice in the experimental group compared with mice in the mock group (Fig 5) ; the serum CEA levels of mice in the experimental group were 21.7 Ϯ 14.9 ng/mL at 3 days, 77.6 Ϯ 56.2 ng/mL at 10 days, 160.0 Ϯ 134.5 ng/mL at 17 days, 183.1 Ϯ 179.8 ng/mL at 24 days, and 220.0 Ϯ 97.9 ng/mL at 38 days postinoculation. Mice in the experimental group exhibited less peritoneal dissemination (Fig 6) than mice in the mock group, and no other pathologic change was observed in the organs of the abdominal cavities (data not shown). Consequently, 13 of the 15 mice in the experimental group survived to 50 days, significantly longer (P Ͻ .01) than those in the mock group (Fig 7) . Because all of the mice in the mock group were dead by 40 days, we observed the mice for only 50 days after the i.p. injection of tumor cells. The i.p. dissemination in the 2 dead mice of the experimental group was more severe than in the other 13 mice because of the serum CEA elevation and the progressive ascites. In particular, serum CEA levels in these two mice had increased to levels similar to those of the mock group (Fig 8) . In short, there was no therapeutic effect on the two mice that died, regardless of the administration of the fusogenic liposomes containing mutated degenerin expression plasmid. Tumor expansion was the cause of death in these two mice as well as in the mock and control groups.
DISCUSSION
MDEG, the mammalian homolog of degenerin, was engineered to produce mutant variants that cause degeneration in both Xenopus oocytes and embryonic hamster kidney cells, as previously demonstrated for other members of the degenerin family. A cascade of events resulting in elevated Na ϩ influx followed by subsequent cell swelling leads to excitotoxic death in the mutant MDEG-transfected cells. 7 These findings led us to speculate that expression of mutant MDEG (MDEG-G430F) induces irreversible disruption of intracellular The serum CEA levels of all mice increased due to the growth of MKN45-P cells injected i.p. The inoculated mice were then divided into three groups: Experimental group (n ϭ 15), mock group (n ϭ 15), and control group (n ϭ 15). The three groups displayed no significant differences in CEA levels on day 3 (one-way ANOVA and post-hoc tests using the Bonferroni/Dunn method). I.p. injection of fusogenic liposome containing plasmids was repeated once a week on each group until 50 days postinoculation. Serum CEA levels were measured each week. F, experimental group treated with fusogenic liposome containing CEApcDNA3 MDEG-G430F plasmid (OD 540 ϭ 0.25); E, mock group treated with fusogenic liposome containing CEApCDNA3 plasmid (OD 540 ϭ 0.25); f, control group treated with fusogenic liposome only. Black arrows indicate i.p. injection of the fusogenic liposome complex. From day 17, there was a significant difference in serum CEA levels between the experimental group and the mock group (P Ͻ .01). During the observation period (until 40 days posttransfection), there was no significant difference between the serum levels in the mock group and the serum levels in the control group.
homeostasis in tumor cells, thereby resulting in cell death.
Tumor-specific promoters such as CEA have advantages for tumor cell targeting compared with the CMV promoter. As shown in Figure 2 , however, their promoter activity levels are not sufficient to express the gene that we are attempting to induce. Therefore, MDEG-G430F was employed because its expression kills tumor cells regardless of the promoter activity. The in vitro results of the present study demonstrated that expression of MDEG-G430F driven by tumor-specific promoters was potent enough to kill cancer cells at a level equivalent to that demonstrated by the CMV promoter. Therefore, we also examined whether our in vitro findings would hold true in an in vivo study.
For the in vivo study, a mouse peritoneal dissemination model with a gastric cancer cell line, MKN45-P, was employed. 8 Peritoneal dissemination is the most frequent mode of gastric cancer expansion and is resistant to therapy; patients in this condition are generally refractory to conventional therapeutic approaches, and the prognosis for peritoneal dissemination is quite poor. Prevention and treatment of peritoneal dissemination is, therefore, one of the most important therapeutic targets for gastric cancer research.
However, delivery of the specific genes into animal cells plays an important role in gene therapy. In this context, fusogenic liposomes, also called hemagglutinating virus of Japan, constitute a unique system that can introduce the materials encapsulated in the liposomes directly and efficiently into tissue cells of living animals in vivo.
11 Unilamellar fusogenic liposomes, an improved fusogenic liposome system, are a very efficient nonviral vector for gene transfer in vitro and in vivo. 12 The present study used this improved fusogenic liposome system.
In the mouse peritoneal dissemination model, an elevation in the serum CEA level reflected growth of cancer cells. Mice whose serum CEA levels were Ͼ1000 Influence of CEA promoter-driving MDEG-G430F on the survival rate of BALB/c mice inoculated with MKN45-P cells. BALB/c mice were inoculated with 1 ϫ 10 6 MKN45-P cells. I.p. injection of fusogenic liposomes containing plasmids was repeated once a week on each group until 50 days postinoculation. That is to say, from 10 days after the inoculation, mice in the experimental group were treated with an i.p. injection of 100 L of fusogenic liposome complex containing CEApCDNA3 MDEG-G430F plasmid (OD 540 ϭ 0.25); mice in the mock group were treated with fusogenic liposomes containing CEApCDNA3 plasmid (OD 540 ϭ 0.25). F, experimental group; E, mock group; f, control group treated with fusogenic liposome only. Black arrows indicate i.p. injection of the fusogenic liposome complex. From day 27, there was a significant difference in the survival rate between the experimental group and the mock group (P Ͻ .01). There was also a significant difference between the experimental group and the control group (P Ͻ .01). During the observation period (until 40 days posttransfection), there was no significant difference in the survival rate between the mock group and the control group. ng/mL eventually died. In contrast, the survival rate of the mice treated with MDEG-G430F driven by the CEA promoter was greatly improved, thus demonstrating that an i.p. injection of fusogenic liposome complex containing MDEG-G430F driven by the CEA promoter is very effective in combating carcinomatous peritonitis originating from a CEA-producing cancer. Furthermore, because overwhelming Na ϩ influx leads to tumor cell death, no additional treatment such as anti-cancer pharmacotherapy is required with this approach, because sodium ions are of the most abundant molecules in extracellular fluids. This is a great advantage for a clinical approach compared with the currently prevailing procedure that combines herpes simplex virus-thymidine kinase and anti-cancer pharmacotherapy.
Although no secondary effects of MDEG-G430F expression have been demonstrated or can be expected, the potent cell-killing effect of transferring the gene of interest by the fusogenic liposome system combined with MDEG-G430F expression irrespective of the transcriptional efficiency of the promoters used can overcome this weakness.
With regard to solid tumors, a therapeutic approach via intravenous (i.v.) administration is indispensable. However, because fusogenic liposomes are captured by erythrocytes, 13 the fusogenic liposome system cannot carry the materials into the target cells via i.v. administration. Further study is needed to attempt an approach against solid tumors with systemic i.v. administration using adenoviral vector.
In conclusion, transferring MDEG-G430F with tumor-specific promoters into cancer cells can achieve effective and selective tumor cell death in vivo, which might serve as a new strategy for cancer gene therapy. Individual change in the serum CEA level of mice in the experimental group. Changes in the serum CEA level of mice in the experimental group were monitored individually. Of the 15 mice in the experimental group, 2 died. Serum CEA levels had increased to levels similar to those in the mock group in these two mice, and they died on days 29 and 35, respectively. Black arrows indicate i.p. injection of the fusogenic liposome complex.
